Company Name: CareDx, Inc.
CareDx, Inc. develops noninvasive diagnostics for use in the surveillance of organ transplant patients. The company’s AlloMap blood test is designed to assist in identifying recipients of heart transplants with stable allograft function who have low probability of moderate to severe acute cellular rejection.
Ticker Symbol: CDNA (NASDAQ)
Company Website: www.caredxinc.com
Headquarters: Brisbane, CA